azelastine/fluticasone / Generic mfg. - LARVOL DELTA

Treatment of allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparison table: Some nasal sprays for seasonal allergic rhinitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Immunology • Inflammation

Efficacy and safety of azelastine hydrochloride and fluticasone propionate nasal spray in treating allergic rhinitis: A randomized controlled trial. (PubMed, Asia Pac Allergy) - "MP-AzeFlu (Dymista; Meda Pharma GmbH & Co., KG), a formulation combining azelastine hydrochloride and fluticasone propionate in a single spray, is superior to fluticasone propionate alone in relieving symptoms and improving the quality of life of patients with allergic rhinitis...Significant differences were not observed between groups. AzeFlu showed effects equivalent to those of MP-AzeFlu in this clinical trial and may benefit Chinese patients with allergic rhinitis.Registration number: CTR20190189 (chinadrugtrials.org.cn/index.html)."

Clinical • Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis (clinicaltrials.gov) - P4 | N=22 | Completed | Sponsor: University of Chicago | Unknown status ➔ Completed

Trial completion • Allergic Rhinitis • Immunology • Inflammation

Clinically Relevant Characterization and Comparison of Ryaltris and Other Anti-Allergic Nasal Sprays. (PubMed, Pharmaceutics) - "The work aims to investigate technological aspects of Ryaltris (mometasone furoate and olopatadine hydrochloride nasal spray) compared to other commercial anti-allergic nasal products, namely, Dymista (azelastine hydrochloride and fluticasone propionate), Nasonex (mometasone furoate), and Avamys (fluticasone furoate). Finally, the intranasal deposition profile of the commercial formulations was determined using a silicon nasal cast. The results highlight in vitro significant differences in terms of viscosity as well as dissolution rate of the nasal products, with Ryaltris showing a higher viscosity and lower flow compared to other products, which, along with a corticosteroid faster dissolution rate than Dymista, suggest a potential advantage in terms of clinical behavior."

Journal

Generic competition and prices for azelastine-fluticasone nasal spray. (PubMed, Int Forum Allergy Rhinol) - "Following generic availability of AZ‒FL, Medicare utilization increased and spending decreased. Retail prices for generic AZ‒FL remain high due to markup by manufacturers and pharmacies."

Journal • Inflammation

A Study Conducted in the Environmental Exposure Chamber (EEC) to Assess Onset of Action of Combination of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Dymista) in the Treatment of Allergic Rhinitis Symptoms Compared to Placebo (EAACI 2024) - "This reduction in symptoms was maintained over the entire post treatment allergen exposure (4 hours). This study supports the claim that those who suffer from allergic rhinitis can have rapid and clinically meaningful symptom relief with Dymista."

Clinical • Allergic Rhinitis • Immunology • Inflammation

BIOEQUIVALENCE STUDY OF AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE 137 Microgram/50 Microgram NASAL SPRAY AND 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Humanis Saglık Anonim Sirketi

New P1 trial • Allergic Rhinitis • Immunology • Inflammation

Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients (clinicaltrials.gov) - P=N/A | N=924 | Completed | Sponsor: Mylan Inc. | Recruiting ➔ Completed

Trial completion • Allergic Rhinitis • Immunology • Inflammation

Allergic Rhinitis Combination Pharmacotherapy Efficacy Study (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: St. Paul's Sinus Centre | N=102 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Allergic Rhinitis • Immunology • Inflammation

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis (clinicaltrials.gov) - P2 | N=136 | Completed | Sponsor: Synmosa Biopharma Corp.

New P2 trial • Allergic Rhinitis • Immunology • Inflammation

Evidence-based use of antihistamines for treatment of allergic conditions. (PubMed, Ann Allergy Asthma Immunol) - "The literature is replete with large meta-analyses and systematic reviews establishing the safety and efficacy of second-generation H1-antihistamines in adult and pediatric allergic rhinitis populations including combination nasal spray agents (ex, MP29-02 or MP-AzeFlu)...Robust data on the regular, not as needed use, of H1-antihistamines for urticaria has been published including in the management of children and pregnant or lactating women. Additionally, H1-antihistamines can also be used in other related allergic conditions such as the secondary symptoms of anaphylaxis to provide patients with greater comfort, as well as in allergic asthma depending on the individual."

Journal • Review • Allergic Rhinitis • Asthma • Dermatology • Immunology • Inflammation • Pediatrics • Pulmonary Disease • Respiratory Diseases • Urticaria

Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients (clinicaltrials.gov) - P=N/A | N=900 | Recruiting | Sponsor: Mylan Inc. | Trial completion date: Oct 2022 ➔ Dec 2023 | Trial primary completion date: Sep 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Allergic Rhinitis • Immunology • Inflammation

The Rising Cost of Rhinologic Medications. (PubMed, Ann Allergy Asthma Immunol) - "The rising cost of highly utilized medications contribute to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations."

Journal • Allergy • Immunology • Otorhinolaryngology

Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia - An Observational Real-World Clinical Study. (PubMed, Patient Prefer Adherence) - "Combination intranasal corticosteroid and antihistamine sprays are a first-line treatment option for allergic rhinitis (AR), of which Azelastine Hydrochloride and Fluticasone Propionate nasal spray (AZE/FLU; Dymista), and Olopatadine Hydrochloride and Mometasone Furoate Monohydrate nasal spray (OLO/MOM; Ryaltris) are currently registered in Australia. Current findings showed that participants using OLO/MOM were more satisfied with their overall treatment compared to participants using AZE/FLU, particularly with sensory attributes, thus highlighting the suitability of OLO/MOM for people with AR who value sensory attributes. Prescribers of AR treatments are encouraged to discuss treatment attributes with patients to facilitate shared decision-making."

Journal • Real-world • Real-world evidence • Allergic Rhinitis • Immunology • Inflammation

Olopatadine/mometasone (Ryaltris) for allergic rhinitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Immunology • Inflammation

Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER) (clinicaltrials.gov) - P3 | N=514 | Not yet recruiting | Sponsor: EMS

New P3 trial • Allergic Rhinitis • Immunology • Inflammation

Real-Life Effectiveness of MP-AzeFlu (Dymista) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale. (PubMed, Pragmat Obs Res) - "MP-AzeFlu (Dymista) comprises intranasal azelastine hydrochloride and fluticasone propionate in a novel formulation delivered in a single device. Symptom improvement was observed at Day 1, sustained for 42 days, and associated with improved sleep quality. MP-AzeFlu significantly improved the QoL of the patients and was well tolerated."

Journal • Allergic Rhinitis • Immunology • Inflammation

Efficacy of Topical Azelastine and Fluticasone Dipropionate Combination in Children With Adenoid Hypertrophy. (PubMed, Ear Nose Throat J) - "In this study, the effectiveness of AZE-FLU nasal spray on AH was investigated for the first time. This treatment provides an effective alternative to the surgical approach in children with uncomplicated adenoid hypertrophy. Using this protocol, 96% of patients were removed from the surgery list."

Journal

"Dymista" (@jason_g_collins)

Dymista Allergen Chamber - Onset of Action Study (clinicaltrials.gov) - P4 | N=216 | Completed | Sponsor: MEDA Pharma GmbH & Co. KG | Recruiting ➔ Completed

Trial completion • Allergic Rhinitis • Immunology

Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients (clinicaltrials.gov) - P=N/A; N=900; Recruiting; Sponsor: Mylan Inc.

Clinical • New trial • Allergic Rhinitis • Immunology

Dymista Allergen Chamber - Onset of Action Study (clinicaltrials.gov) - P4; N=216; Recruiting; Sponsor: MEDA Pharma GmbH & Co. KG; Trial completion date: Jul 2021 ➔ Jan 2022; Trial primary completion date: Jul 2021 ➔ Jan 2022

Clinical • Trial completion date • Trial primary completion date • Allergic Rhinitis • Immunology

BIODYMF: Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate (clinicaltrials.gov) - P=N/A; N=0; Withdrawn; Sponsor: University Hospital, Ghent; N=24 ➔ 0; Recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal

Drugs for allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology